葡萄糖类-1受体 (GLP-1R) 信号传导:为功能性Gs蛋白选择性GPCR做出理由
Anastasios Lymperopoulos1, Victoria L Altsman1, Renee A Stoicovy1
1Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences (Pharmacology), Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328-2018, USA.
International journal of molecular sciences
|August 14, 2025
概括
葡萄糖类-1受体 (GLP-1R) 激动剂显示治疗成功. 有证据表明GLP-1R作为Gs选择性受体起作用,与GIPR不同,影响肥胖和糖尿病的药物开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂是糖尿病和肥胖症的成功治疗方法.
- 葡萄糖家族受体 (GCGR,GLP-1R,GIPR) 是参与胰岛素分泌的B1类G蛋白结合受体 (GPCR).
- GPCRs通常通过βarrestin相互作用去敏感,但GLP-1R可能会抵抗这种作用.
研究的目的:
- 与GIPR相比,研究GLP-1R的信号和脱敏机制.
- 提供GLP-1R作为Gs选择性受体的证据.
- 讨论开发针对GLP-1R.R的多联体的含义.
主要方法:
- 对GLP-1R和GIPR信号通路的实验证据的审查.
- 分析涉及G蛋白和βarrestins的GPCR脱敏机制.
- 对受体贩运和脂质相互作用的讨论.
主要成果:
- GLP-1R信号的特点是强大的和长时间的cAMP产生,这表明缺乏无敏化.
- 吉普尔信号传递严重涉及βarrestins,导致显著的脱敏,内化和下调.
- GLP-1R表现出与Gs选择性受体相一致的特性,与GIPR不同.
结论:
- GLP-1R似乎是一个表型Gs选择性受体,抵抗脱敏.
- GLP-1R和GIPR的显著信号和脱敏特征对治疗策略有重大影响.
- 了解这些差异对于针对代谢疾病的基于GLP-1R的新型多联体的合理设计至关重要.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
GPCR Desensitization
6.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.5K
G Protein-coupled Receptors
13.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.4K
Transducer Mechanism: G Protein–Coupled Receptors
2.4K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.4K
Activation and Inactivation of G Proteins
7.6K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
7.6K
Glucagon-like Receptor Agonists
418
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
418


